IMW 2021 | MRD: from clinical trials to clinical practice
Katja Weisel, MD, of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, shares her views on the viability of measurable residual disease (MRD) assessment in the treatment of myeloma, and explains why the possibility brings hope in the multiple myeloma treatment field. Currently, the strengths of MRD have only been demonstrated in clinical trials and not yet in routine clinical practice. Dr Weisel reports that the major question is not whether MRD measurement is performed using flow cytometry or next-generation sequencing, but whether MRD assessment can be used to tailor treatment in routine clinical practice. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Katja Weisel, MD, has received institutional grant support from Amgen, BMS/Celgene, GSK and Sanofi; and has received honoraria from AbbVie, Amgen, Adaptive Biotech, BMS/Celgene, Janssen, GSK, Karyopharm, Novartis, Oncopeptides, Pfizer, Roche Pharma, Takeda and Sanofi.
